An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib.

Datos básicos

ENSAYO CLÍNICO CLOU064A2306B HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2026

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

NOVARTIS PHARMA AG

Cita

Compartir